Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Immutep Ltd. IMMP

10 fiscal years on record · AUD · FY2024 reported · SEC filings only
AUD 10.3M
▲ 31.8% YoY
AUD -61.4M
AUD -62.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

AUD 10.3M
Revenue, FY2024 · full 10-year series below
Revenue AUD M Net income AUD M
FY2024 · Revenue 10.3 · Net income -61.4
10.0M20.0M-25.0M-50.0M
2015201820212024
Compound annual growth
+15.2%
−8.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −8.9% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−595 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Net -594.6%
-200%-400%-600%
201520192024
ROE
FY2024 · ROE -36.9%
-50%-100%-150%
201520192024
Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Each AUD of equity lost 37 cents this year.

Cash & shareholders

AUD 0.00
returned in FY2024 · dividends + net buybacks
Free cash flow AUD M
FY2024 · FCF -62.1
-25.0M-50.0M
201520192024

Total assetsAUD 157.0M
EquityAUD 143.6M
CashAUD 67.4M
DepositsAUD 62.3M
Current ratio11.69×

Equity funds 91% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · AUD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IMMP, 10-year financial record
Metric 2024202320222021202020192018201720162015
Revenue AUD B0.00.00.00.00.00.00.00.00.00.0
Operating income AUD B◌◌◌◌◌◌◌◌◌◌
EBITDA AUD B◌◌◌◌◌◌◌◌◌◌
Income tax AUD B0.00.00.00.00.00.00.00.0−0.0−0.0
Net income AUD B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1
Free cash flow AUD B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted AUD −0.04−0.04−0.04−0.04−0.05−0.03−5.29−4.63−0.40−2.78
Dividend / sh AUD ◌◌◌◌◌◌◌◌◌◌
Payout %−0−0−0−0−0−0−0−0−0—
ROE %−36.9−26.2−34.6−38.5−56.1−46.7−63.4−42.4−30.3−175.6

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 4 failures in 39 reconciliationsAUDITED

Reconciled in 6 of the 10 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Eight checks were skipped: EPS is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency4 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
Data on record since2015

Share this section

Download image